Accurate identification of lung cancer in the early phase by serum exosomal miR-1271-5p.

Abstract

e20029 Background: Exosomal miRNAs are associated with the proliferation, migration, and invasion of lung cancer cells. We aim to investigate the clinical significance of serum exosomal miR-1271-5p in early-stage lung cancer (ESLC) mainly characterized by pulmonary nodules to push forward the prevention and treatment of lung cancer. Methods: The serum exosome (sEVs) miR-1271-5p was obtained from a total of 134 subjects from the patients with ESLC and the benign nodule (BLN) and healthy controls, and the expression level of miR-1271-5p were detected by RT-qPCR. Through analysis the clinical feature and CT (Computed Tomography) imaging finding of the subjects confirmed by pathology, independent risk factors for ESLC were obtained according to univariate and multivariate logistic regression analysis. R software was incorporated to build a mathematical prediction model of nomogram, and the clinical significance of sEVs-miR-1271-5p in the prediction and diagnosis of ESLC was verified by ROC curve. Results: The relative expression of sEVs-miR-1271-5p was lower in the patients with ESLC than the patients with BLN and healthy controls. The AUC value of the ESLC predicted by sEVs-miR-1271-5p was 0.9845 (95%CI: 0.9649-1.000, P < 0.0001). The results of multi-factor logistic regression analysis showed that gender (OR = 0.213, p = 0.046), nodule diameter (OR = 0.794, p = 0.031), lobulation (OR = 0.013, p < 0.0001), and sEVs-miR-1271-5p (OR = 0.014, p = 0.037) were independent risk factors for ESLC. Based on these independent risk factors, a prediction model for ESLC was established, with an AUC value of 0.8810 (95% CI: 0.8076-0.9553, P < 0.0001), the sensitivity, specificity, positive and negative predictive value and accuracy of the model were 85%, 80.43%, 79.07%, 86.05% and 82.56% respectively. Conclusions: Serum exosomal miR-1271-5p may break through the early diagnosis of lung cancer and provide important therapeutic targets.